Pulse Biosciences Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Pulse Biosciences.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth	16.2%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

Jan 20

Pulse Biosciences' CellFX System U.S. application moves forward for general dermatology indication

Jan 12

We're Keeping An Eye On Pulse Biosciences' (NASDAQ:PLSE) Cash Burn Rate

Dec 16

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pulse Biosciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:PLSE - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2023	N/A	-42	N/A	N/A	N/A
9/30/2023	0	-39	-34	-34	N/A
6/30/2023	0	-47	-35	-34	N/A
3/31/2023	0	-51	-38	-38	N/A
12/31/2022	1	-59	-47	-47	N/A
9/30/2022	2	-65	-52	-52	N/A
6/30/2022	2	-61	-55	-54	N/A
3/31/2022	2	-62	-59	-58	N/A
12/31/2021	1	-64	-55	-54	N/A
9/30/2021	1	-62	-51	-51	N/A
6/30/2021	N/A	-61	-46	-46	N/A
3/31/2021	N/A	-57	-38	-37	N/A
12/31/2020	N/A	-50	-36	-35	N/A
9/30/2020	N/A	-50	-35	-35	N/A
6/30/2020	N/A	-49	-35	-35	N/A
3/31/2020	N/A	-49	-37	-36	N/A
12/31/2019	N/A	-47	-35	-34	N/A
9/30/2019	N/A	-42	-32	-31	N/A
6/30/2019	N/A	-41	-30	-30	N/A
3/31/2019	N/A	-39	-26	-26	N/A
12/31/2018	N/A	-38	-24	-24	N/A
9/30/2018	N/A	-37	-22	-22	N/A
6/30/2018	N/A	-34	-18	-18	N/A
3/31/2018	N/A	-31	-16	-14	N/A
12/31/2017	N/A	-26	-14	-11	N/A
9/30/2017	N/A	-20	N/A	-9	N/A
6/30/2017	N/A	-15	N/A	-8	N/A
3/31/2017	N/A	-11	N/A	-9	N/A
12/31/2016	N/A	-10	N/A	-8	N/A
9/30/2016	N/A	-8	N/A	-7	N/A
6/30/2016	N/A	-6	N/A	-6	N/A
3/31/2016	N/A	-4	N/A	-4	N/A
12/31/2015	N/A	-3	N/A	-3	N/A
9/30/2015	N/A	-2	N/A	-2	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if PLSE's forecast earnings growth is above the savings rate (2.4%).

Earnings vs Market: Insufficient data to determine if PLSE's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if PLSE's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if PLSE's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if PLSE's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PLSE's Return on Equity is forecast to be high in 3 years time

Pulse Biosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus revenue estimates fall by 31%

Consensus forecasts updated

Price target decreased to US$11.17

Consensus forecasts updated

Price target decreased to US$35.33

Price target decreased to US$35.33

Recent updates

Pulse Biosciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pulse Biosciences, Inc., Annual General Meeting, Jun 06, 2024

Pulse Biosciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System

Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

Pulse Biosciences, Inc. Announces First-In-Human Procedures with its Novel CellFX Nanosecond Pulsed Field Ablation Cardiac Catheter

Executive Chairman exercised options to buy US$382k worth of stock.

Executive Chairman recently bought US$1.1m worth of stock

Pulse Biosciences, Inc. Announces Filing of Premarket Notification 510(k) to U.S. Food and Drug Administration for its Novel CellFX nsPFA Percutaneous Electrode

Chief Strategy Officer recently bought US$105k worth of stock

Executive Chairman exercised options to buy US$68k worth of stock.

Pulse Biosciences, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Pulse Biosciences, Inc. Appoints Dr. Niv Ad as Chief Science Officer, Cardiac Surgery

We Think Pulse Biosciences (NASDAQ:PLSE) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Pulse Biosciences, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Executive Chairman exercised options to buy US$881k worth of stock.

Executive Chairman exercised options to buy US$36m worth of stock.

Independent Director exercised options to buy US$543k worth of stock.

Pulse Biosciences, Inc. Appoints f Gansevoort 'Gan' Dunnington, M.D. as Its Chief Medical Officer

Pulse Biosciences (NASDAQ:PLSE) Has Debt But No Earnings; Should You Worry?

Pulse Biosciences, Inc. Announces Resignation of Sandra Gardiner as Chief Financial Officer

Pulse Biosciences, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Chief Strategy Officer & Director recently bought US$70k worth of stock

Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions

Pulse Biosciences, Inc. Announces FDA 510(k) Clearance for the Treatment of Sebaceous Hyperplasia

Pulse Biosciences, Inc. Announces Executive Changes

Pulse Biosciences appoints Kevin Danahy as CEO; Darrin Uecker to serve as CTO

Consensus revenue estimates fall by 31%

Pulse Biosciences, Inc. Receives FDA 510(K) Clearance of Expanded Energy Settings for Use with the CellFX System

Pulse Biosciences, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Pulse Biosciences, Inc.(NasdaqCM:PLSE) dropped from Russell 2000 Dynamic Index

Pulse Biosciences, Inc. has completed a Composite Units Offering in the amount of $15 million.

Consensus forecasts updated

Price target decreased to US$11.17

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pulse Biosciences, Inc

Consensus forecasts updated

Companies Like Pulse Biosciences (NASDAQ:PLSE) Could Be Quite Risky

Pulse Biosciences, Inc., Annual General Meeting, May 19, 2022

Pulse Biosciences, Inc. to Report Q4, 2021 Results on Mar 31, 2022

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Pulse Biosciences, Inc

Pulse Biosciences Announces the Appointment of Kevin Danahy as Chief Commercial Officer

Pulse Biosciences, Inc Provides an Update on Recent FDA 510(k) Submission

Price target decreased to US$35.33

Price target decreased to US$35.33

Pulse Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter 2021

Forecast to breakeven in 2024

Is Pulse Biosciences (NASDAQ:PLSE) Using Debt In A Risky Way?

Consensus forecasts updated

Price target decreased to US$37.95

Independent Chairman of the Board recently bought US$50m worth of stock

Pulse Biosciences, Inc. Announces First CellFX Procedure Performed in Canada

Pulse Biosciences Announces Health Canada Approval for CellFX® System

Pulse Biosciences gets Health Canada approval for CellFX System

Consensus forecasts updated

Pulse Biosciences® Presents Clinical Study Results of Nano-Pulse Stimulation™ Technology to Clear Benign Lesions at the American Society for Laser Medicine and Surgery (ASLMS) 2021 Virtual Annual Conference

Is Pulse Biosciences (NASDAQ:PLSE) In A Good Position To Invest In Growth?

Who Has Been Buying Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares?

Pulse Biosciences Announces First CellFX Procedures

Pulse Biosciences Announces Start of Controlled Launch of the CellFX System®

Pulse Biosciences, Inc. to Report Q4, 2020 Results on Feb 22, 2021

Pulse Biosciences, Inc. Announces FDA Clearance for the CellFX® System

Pulse Biosciences establishes at-the-market equity program

New 90-day high: US$36.62

Price target raised to US$40.00

What Percentage Of Pulse Biosciences, Inc. (NASDAQ:PLSE) Shares Do Insiders Own?

New 90-day high: US$26.94

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress